Skip to content
Screener

Relmada Therapeutics, Inc. RLMD Q1 2026 earnings

Reported May 12, 2026 · After market close

EPS-$0.22Miss by $0.04
EPS estimate-$0.18

Next report

Nov 12, 2026 (in 2 months)
EPS estimate-$0.14

Financials

Q1 2026

Income statement

See full
Operating income-$19.5M-6.8%
Net income-$19.1M-8.5%
EPS (diluted)-$0.22+62.1%

Balance sheet

See full
Cash & equivalents$9.8M+750%
Total equity$218.7M+875%
Total assets$235.4M+750%

Cash flow

See full
Operating cash flow-$15.1M+16.6%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$730.04M+8,046%

Returns & leverage

See full
Return on equity-48.8%-20.0pp
Current ratio18.3×+13.0×

FAQ

When did Relmada Therapeutics, Inc. report Q1 2026 earnings?
Relmada Therapeutics, Inc. (RLMD) reported Q1 2026 earnings on May 12, 2026 after market close.
What were Relmada Therapeutics, Inc.'s Q1 2026 revenue and EPS?
Relmada Therapeutics, Inc. reported eps of $-0.22 for Q1 2026.
Did Relmada Therapeutics, Inc. beat estimates in Q1 2026?
EPS missed the consensus estimate of $-0.18 by $0.04.
How did Relmada Therapeutics, Inc.'s Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 62.1% from $-0.58.
Where can I find Relmada Therapeutics, Inc.'s Q1 2026 SEC filings?
You can read the 8-K earnings release (0001213900-26-055164) and the 10-Q periodic report (0001213900-26-055059) directly on SEC EDGAR. The filing index links above go to sec.gov.